- Braster (WA:BRAR) was founded in 2008 by five Polish scientists in order to commercialize their research in the area of liquid crystals. The scientists developed a new method of mixing liquid-crystal compounds that allowed the creation of corresponding matrices, which makes the early diagnosis of breast cancer much cheaper, efficient and secure. In the last years, BRASTER has developed a prototype of its BRASTER Tester device, which uses the matrices, and secured patents for its technology in already c. 20 countries. They are valid until c. 2030.
- At the end of 2014, the company announced a change of its strategy, which now focuses on telemedicine services for women instead of product sales to medical practitioners. Upon completion of the necessary investments in the production facility for matrices, software development, data center and marketing, BRASTER plans to earn money from selling the devices, 2-year subscriptions and medical consultancies. The company wants to sell the BRASTER Tester itself (own sales team, online shop), through pharmacies and drug stores or on a white-label basis. In our view, wealthy countries such as Germany, France or UK are much more promising for the company due to higher incomes and willingness to spend money on healthcare from own pocket.
- According to GLOBOCAN, breast cancer is the most serious type of cancer in case of women with a share of 25.2% (1.8m new cases in 2015E) in total diagnosed cases and a death rate of >30%. Most of the diagnosed breast cancer cases occur in Western and Northern Europe and the US, making the malignancy a civilization disease. According to BCC Research and Research and Markets, the global market for telemedicine is expected to grow by 2019E on average by 17.7% y-o-y to USD 43.4bn (thereof: home-based telehealth at a CAGR of 24%), while in Europe the CAGR 11-19E is forecast at 12.8% to USD 12.6bn.
East Value Research GmbH has taken several measures to prevent conflicts of interest. One of these is that its employees are prohibited to trade in stocks from its coverage.
In addition, its employees are not permitted to accept gifts or any other beneficial contributions from individuals, who have an interest in the content of our research publications.
3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or
remove ads
.